The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Capizzi, R L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

amifostine; chemotherapy; cytoprotection; radiotherapy

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; MICE; NEOPLASMS, EXPERIMENTAL; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RATS;

EID: 0029907683     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00333-4     Document Type: Article

References (88)

1. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or highgrade non-Hodgkin's lymphoma
2. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide
3. Intensive chemotherapy with cyclophosphamide carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease
4. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging
5. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas
6. Cysteine protection against X irradiation
7. Biological characteristics of some improved radioprotectors
8. Differential chemoprotection of normal and malignant tissues
9. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumor properties
10. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine
11. The role of WR-2721 in radiotherapy and/or chemotherapy
12. Treatment of tumors with the combination of WR-2721 and cisdichlorodiammineplatinum (II) or cyclophosphamide
13. A more general role for WR-2721 in cancer therapy
14. The role of WR-2721 in radiotherapy and/or chemotherapy
15. WR-2721 chemoprotection of doxorubicin toxicity in mice
16. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro (abstract)
17. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune deficient mouse preliminary results
18. Human pharmacokinetics of WR-2721
19. Pharmacokinetics of WR-2721
20. Pharmacokinetics of amifostine in cancer patients: evidence for saturable metabolism
21. Metabolic pathway of WR2721 (ethyol, amifostine) in the BALB/c mouse
22. Measurement of ethiofos (WR-2721) in plasma: preliminary pharmacokinetics in the beagle
23. A method for the combined measurement of ethiofos and WR-1065 in plasma: application to pharmacokinetic experiments with ethiofos and its metabolites
24. Protection against radiation-induced mutagenesis at the hprt locus by spermine and N,N″ (dithiodi-2, l-ethanediyl) bis-1, 3-propanediamine (WR33278)
25. Mode of action of some substances which protect against the lethal effect of x-rays
26. Localized areas of high alkaline phosphatase activity in endothelium of arteries
27. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug
28. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection
29. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721
30. Biochemical determinants of the cyoprotective effect of amifostine
31. Hydrolysis of WR-2721 by mouse liver cell fractions
32. A liquid chromatographic electrochemical assay for S-2-(3-aminopropylamino) ethylphosphorothioate (WR-2721) in human plasma
33. 35S-labeled WR-2721 in normal and malignant tissues of the mouse
34. 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913)
35. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
36. Clinical experiences with a chemical radioprotector in tumor radiotherapy: WR-2721
37. Influence of WR-2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo
38. Seventh International Conference on Chemical Modifiers of Cancer Treatment
39. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate
40. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response
41. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action
42. Enhancement of topoisomerase I-mediated unwinding of supercoiled DNA by the radioprotector WR-33278
43. N-(2-Mercaptoethyl)-l,3 propanediamine (WR-1065) protects thymocytes from programmed cell death
44. Preclinical evaluation of WR-151327: an orally active chemotherapy protector
45. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer
46. Amifostine: potential for clinically useful cytoprotection
47. Phase I trial of carboplatin and amifostine (WR-2721)
48. Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil
49. Amifostine protects MRC-5 human lung fibroblasts from taxol toxicity without reducing its cytotoxic effect against human nonsmall cell lung cancer cells
50. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721
51. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721
52. The modification of melphalan toxicity in tumor-bearing mice by S-2-3-aminopropylamino-ethylphosphorothioic acid (Wr-2721)
53. Effects of the modulating agent WR-2721 on myelotoxicity and antitumor activity in carboplatin-treated mice
54. Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds
55. A study of the effect of WR-2721 on human acute lymphoblastic leukemia (ALL) cells purged with 4-hydroperoxycyclophosphamide (4-HC) or a combination purging regimen
56. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxyclyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
57. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging
58. Purging of small-cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 photo treatment
59. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hematopoietic reconstitution and increase survival
60. Enhanced recovery from supralethal radiation exposure using combined modality WR-2721 plus recombinant human (rh) G-CSF
61. Granulocyte colony-stimulating factor and amifostine (ethyol) synergize to enhance hematopoietic reconstitution and increase survival in irradiated animals
62. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse
63. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278
64. Reduction of tetrachloro (dl-trans) 1, 2-diaminocyclohexaneplatinum (IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2 (aminopropylamino) ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat
65. Cisplatin nephrotoxicity: a review
66. Methods of reduction of cisplatin nephrotoxicity
67. Radiation and the small intestine
68. The effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) on intestinal crypt survival
69. Intracolonic WR 2721 protection of the rat colon from acute radiation injury
70. Cisplatin neuropathy: risk factors, prognosis and protection by WR-2721
71. Properties of WR-2721 (ethiofos) as modulator of cisplatin-induced neurotoxocity studied at the ultrastructural level in the pond snail Lymnaea stagnalis
72. Prophylaxis of kanamycin-induced ototoxicity by a radioprotectant
73. Oxygendependent protection of radiation lung damage in mice by WR 2721
74. Selective cardioprotection of rat heart myocytes exposed to DNA intercalating agents using amifostine (WR-2721) and its dephosphorylated metabolite actifostine (WR-1065)
75. Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland
76. Short-term radioprotective effects of WR-2721 on the rat parotid glands
77. Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice
78. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)ethylphosphorothioic acid
79. 60Co gamma rays in mice
80. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthineguanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation
81. 60Co X-ray and fission-spectrum neutron-induced chromosome damage in V79 cells
82. Cell cycle redistribution of cultured cells after treatment with chemical radiation protectors
83. Concentration-dependent protection against X-ray-induced chromosome aberrations in human lymphocytes by the aminothiol WR-1065
84. The radioprotector WR1065 reduces radiation-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in V79 cells
85. Radiation protectors: the unexpected benefits
86. Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells
87. Protection against cisdiamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol